Recovery of genetically defined murine norovirus in tissue culture by using a fowlpox virus expressing T7 RNA polymerase by Chaudhry, Yasmin et al.
Recovery of genetically defined murine norovirus in
tissue culture by using a fowlpox virus expressing
T7 RNA polymerase
Yasmin Chaudhry,
1 Michael A. Skinner
2 and Ian G. Goodfellow
1
Correspondence
Ian G. Goodfellow
I.Goodfellow@imperial.ac.uk
1Calicivirus Research Group, Department of Virology, Faculty of Medicine, Imperial College London,
St Mary’s Campus, Norfolk Place, London W2 1PG, UK
2Vaccine Vector Group, Department of Virology, Faculty of Medicine, Imperial College London,
St Mary’s Campus, Norfolk Place, London W2 1PG, UK
Received 21 February 2007
Accepted 19 April 2007
Despite the significant disease burden caused by human norovirus infection, an efficient
tissue-culture system for these viruses remains elusive. Murine norovirus (MNV) is an ideal
surrogate for the study of norovirus biology, as the virus replicates efficiently in tissue culture and a
low-cost animal model is readily available. In this report, a reverse-genetics system for MNV is
described, using a fowlpox virus (FWPV) recombinant expressing T7 RNA polymerase to recover
genetically defined MNV in tissue culture for the first time. These studies demonstrated that
approaches that have proved successful for other members of the family Caliciviridae failed to
lead to recovery of MNV. This was due to our observation that vaccinia virus infection had a
negative effect on MNV replication. In contrast, FWPV infection had no deleterious effect and
allowed the recovery of infectious MNV from cells previously transfected with MNV cDNA
constructs. These studies also indicated that the nature of the 39-terminal nucleotide is critical for
efficient virus recovery and that inclusion of a hepatitis delta virus ribozyme at the 39 end can
increase the efficiency with which virus is recovered. This system now allows the recovery of
genetically defined noroviruses and will facilitate the analysis of the effects of genetic variation on
norovirus pathogenesis.
INTRODUCTION
Positive-strand RNA viruses of the family Caliciviridae are
responsible for many diseases in both man and animals.
Those that infect humans, namely members of the genera
Norovirus and Sapovirus, are a major cause of acute
gastroenteritis and are thought to be responsible for .85%
of all non-bacterial gastroenteritis outbreaks in Europe
between 1995 and 2000 (Lopman et al., 2003).
The calicivirus positive-sense, single-strand RNA genome is
approximately 7.5 kb in length, encodes three open reading
frames and is linked covalently to the virus-encoded
protein VPg (Fig. 1a). During virus replication, a
subgenomic RNA is produced, encoding the major and
minor capsid proteins VP1 and VP2, respectively (Fig. 1a).
Despite the major disease burden that caliciviruses cause,
we know little with regard to how these viruses replicate
and, hence, the identification of potential antivirals and
therapeutics has been hindered. This is primarily due to the
fact that the human caliciviruses do not replicate efficiently
in tissue culture. Although recent reports have demon-
strated genome replication and encapsidation by using a
vaccinia virus (VACV) expression system (Asanaka et al.,
2005; Katayama et al., 2006), the mechanism of synthesis of
this RNA and whether it represents authentic VPg-linked
viral RNA are still not known. The subgenomic RNA
produced from a full-length cDNA clone in one of these
systems is not translated, suggesting that it is not VPg-
linked (Katayama et al., 2006). A recent report would also
suggest that cell lines containing a Norwalk virus replicon
can be generated at low frequency (Chang et al., 2006).
This lack of an efficient, fully permissive tissue-culture
system for human noroviruses has slowed the analysis of
the molecular mechanisms used for norovirus genome
translation and replication.
To date, functional studies on calicivirus replication have
focused on animal caliciviruses, namely feline calicivirus
(FCV), porcine enteric calicivirus (PEC; Chang et al., 2002)
and the recently identified murine norovirus (MNV) (Karst
et al., 2003). The identification of MNV represents a signifi-
cantadvanceinthestudy ofnorovirusbiology,asitreplicates
efficiently in tissue culture and there is a small-animal model
available(Karstetal.,2003;Wobusetal.,2004).Theabilityto
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reverse genetics would provide the first opportunity to
understandtherelationshipbetweenthebasicmechanismsof
norovirus replication in tissue culture and pathogenesis in a
naturalhost.Todate,however,noreverse-geneticssystemhas
been reported. Here, we describe a reverse-genetics system
that allows the recovery of genetically defined noroviruses in
tissue culture. We demonstrate that the traditional VACV-
based T7 RNA polymerase delivery system failed to allow the
recovery of MNV, due to an inhibitory effect of VACV
infection on MNV replication. In contrast, the fowlpox virus
(FWPV) T7 RNA polymerase system, which has proved
successful for recovery of positive-strand viruses (infectious
bronchitis virus; Casais et al., 2001), negative-strand viruses
(Newcastle disease virus and rinderpest virus; Peeters et al.,
1999;Dasetal.,2000)andabisegmented,double-strandRNA
virus(infectiousbursaldiseasevirus;Bootetal.,1999),hadno
deleterious effect on MNV replication and could be used to
recover genetically defined MNV in tissue culture.
METHODS
Materials. MNV 1 strain CW1, the murine macrophage line RAW
264.7 and antisera to the MNV VP1 protein were kindly supplied by
Herbert Virgin IV (Washington University in Saint Louis, MO, USA).
MVA-T7 (Wyatt et al., 1995) was kindly supplied by Bernie Moss
(NIH, Bethesda, MA, USA). Rabbit polyclonal antisera to the MNV
NS7 RNA-dependent RNA polymerase and VP2 proteins were
generated against proteins expressed in and purified from
Escherichia coli as poly-histidine-tagged proteins (data not shown).
Both NS7 and VP2 were purified under denaturing conditions (8 M
urea) on nickel agarose and used for immunization of New Zealand
White rabbits. All immunizations and test bleeds were carried out by
Eurogentec.
All cells were maintained in Dulbecco’s modified Eagle’s medium
(Gibco) containing 10% fetal calf serum. The Huh 7.5 cell line was
kindly provided by Charlie Rice (Rockefeller University, NY, USA).
The BSR-T7 cell line was obtained from Karl-Klaus Conzelmann
(Ludwig Maximilians University, Munich, Germany).
Generation of MNV expression constructs. A full-length cDNA
clone of MNV 1 CW1 matching the passage 3 consensus sequence
(Wobus et al., 2004), referred to as p20.3 by Sosnovtsev et al. (2006),
was supplied by Herbert Virgin IV (Washington University in Saint
Louis, MO, USA). For clarity, this construct, containing the MNV 1
genome under the control of a truncated T7 RNA polymerase
promoter, will be hereafter referred to as pT7:MNV-G. A derivative
of this construct (pT7:MNV-G
FS), containing a frame shift in the
RNA-dependent RNA polymerase [NS7 in Fig. 1(a)], was generated by
linearization with XhoI, followed by mung-bean nuclease digestion
and religation. A transfer vector containing the AfeI–SacII fragment
of the MNV-1 genome (pSL301:MNV AfeI–SacII) was generated
by cloning the fragment into pSL301 (Invitrogen). To repair the
Fig. 1. Diagrammatic representation of the MNV genome and the constructs used during this study. (a) Proteolytic-cleavage
map of the MNV 1 genome as demonstrated by Sosnovtsev et al. (2006). Text in italics highlights the nomenclature as proposed
by Sosnovtsev et al. (2006). The caspase 3 cleavage sites in NS1/2 and the position of the subgenomic RNA are also
indicated. (b) Schematic representation of the constructs used during this study. The positions of the restriction sites used
during this study, the active site in the viral RNA-dependent RNA polymerase NS7 and the 39-terminal nucleotide upstream of
the poly-A tail are indicated. See Methods for specific details of each construct.
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FS, the AfeI–SacII fragment
from the transfer vector pSL301:MNV AfeI–SacII was inserted into
pT7:MNV-G
FS to generate pT7:MNV-G
FS/R.
A BglII restriction site was introduced at position 3959 in the MNV
genome by the introduction of a single-nucleotide change (C to A) at
position 3959 to generate pT7:MNV-G/BglII. The restriction site was
introduced by PCR amplification of the region using the primers
IGIC44 and 4450R (See Supplementary Table S1, available in JGV
Online), digestion with AfeI and KpnI and subsequent insertion into
the pSL301:MNV AfeI–SacII transfer vector (see above). The
mutated fragment was subcloned into pT7:MNV-G via the AfeI
and SacII sites. Insertion of the desired mutation, which did not affect
the encoded polypeptide sequence, was confirmed by sequencing.
To insert a hepatitis delta virus ribozyme into pT7:MNV-G at the 39
end of the genome and to repair the 39-terminal nucleotide, a
derivative of the ribozyme containing a 59 NheI site was PCR-
amplified from pRZ (Walker et al., 2003) using the primers PUC-F
and PUC-R (see Supplementary Table S1, available in JGV Online).
The resultant PCR product was digested with NheI and ligated to the
NheI-digested MNV subgenomic PCR product generated by using
primers IGIC21 and IGIC37 (see Supplementary Table S1, available in
JGV Online). The ligated product was subsequently digested with
SacII and EcoRV and inserted into pT7:MNV-G that had been
digested with SacII and SnaBI. The resultant plasmid, pT7:MNV-G
39Rz, contained the MNV genomic RNA flanked by a truncated T7
RNA polymerase promoter at the 59 end and a hepatitis delta virus
ribozyme at the 39 end. The RNA produced from this construct
contained no additional non-viral nucleotides. A similar construct
that lacked the 39 ribozyme, but which contained a correct 39-
terminal nucleotide, referred to as pT7:MNV-G 39Rp, was generated
by ligation of the 39 SacII–NheI fragment from pT7:MNV-G 39Rz
with SacII- and SnaBI-digested pT7:MNV. The resulting construct,
pT7:MNV-G 39Rp, was identical to pT7:MNV-G 39Rz, but lacked
the 39 hepatitis delta virus ribozyme.
The MNV 1 subgenomic RNA cDNA expression construct
pT7:MNV-SG was generated by RT-PCR amplification of RNA
purified from MNV 1 CW1-infected cells, using primers IGIC21 and
IGIC22 (see Supplementary Table S1, available in JGV Online). The
amplified product was digested with NotI and SwaI and inserted into
pTriEx1.1 (Novagen) between the NotI and MscI sites. The construct
was then sequenced fully to confirm that it matched the reported
CW1 passage 3 consensus sequence.
Virus recovery and characterization. Cells were infected with
poxviruses expressing T7 RNA polymerase at an m.o.i. (based on the
virus titre in chick embryo fibroblasts) of 0.5–1.0 p.f.u. per cell. Each
cDNA expression construct or VPg-linked viral RNA, purified as
described previously (Chaudhry et al., 2006), was subsequently
transfected (1 mg) by using Lipofectamine 2000 according to the
manufacturer’s instructions (Invitrogen). To analyse protein expres-
sion, cells were harvested 24 h post-transfection for Western blot
analysis. To examine the presence of infectious norovirus, cells were
harvested 24–72 h post-transfection, virus was released by two freeze–
thaw cycles and the titres of virus were determined as TCID50 in RAW
264.7 cells, using microscopic visualization for the appearance of
cytopathic effect. In some cases, plaque morphology was also
examined by plaque assay (Wobus et al., 2004). One-step growth-
curve analysis was performed by infecting RAW 264.7 cells at an
m.o.i. of 6.0 per cell. Samples were incubated at 37 uC and frozen at
280 uC at various times post-infection. Following two freeze–thaw
cycles, the virus titre was determined by TCID50 on RAW 264.7 cells.
Identification of nuclease-resistant, encapsidated MNV RNA.
To remove unencapsidated MNV RNA or excess cDNA, clarified
lysates from transfected cells were treated with DNase I
(10 units ml
21), RNase A (10 units ml
21) and RNase T1
(400 units ml
21)a t3 7uC for 2 h. Encapsidated RNA was partially
purified by centrifugation through a 30% sucrose cushion for 1 h at
55000 r.p.m. using a Beckman SW55 Ti rotor. The viral pellet was
DNase- and RNase-treated prior to extraction of the viral RNA, which
used the GenElute system (Sigma). The viral RNA was detected by
RT-PCR amplification using the primers 7155F and 7400R (see
Supplementary Table S1, available in JGV Online), resulting in the
amplification of a 258 bp product.
Sequence and RT-PCR analyses of recovered viruses. To
determine the sequence of the viruses recovered from cDNA, RAW
264.7 cells were infected with the recovered viruses at an m.o.i. of 3.0
and viral RNA was prepared 24 h post-infection by using the
GenElute system (Sigma). Seven overlapping PCR products were
amplified, covering the entire genome, and the sequence was
determined by using a series of primers (Wobus et al., 2004). To
determine the sequence of the 59 and 39 ends, 59 and 39 rapid
amplification of cDNA ends (RACE) was performed by using the
Advantage RACE system (Clontech). Sequence analysis and contig
generation were performed by using Vector NTI (Invitrogen).
RESULTS
VACV infection inhibits MNV replication
Previous calicivirus reverse-genetics systems have relied on
the transfection of either in vitro-transcribed, 59-capped
calicivirus genomic RNA (Chang et al., 2005; Sosnovtsev
& Green, 1995) or cDNA constructs, followed by delivery
of T7 RNA polymerase using a VACV recombinant
(Sosnovtsev et al., 2002; Thumfart & Meyers, 2002). A
recent report on rabbit hemorrhagic disease virus (RHDV)
has also demonstrated that in vitro-transcribed, uncapped
RNA is infectious when transfected into cells or delivered
directly to the liver in vivo (Liu et al., 2006). Attempts to
recover MNV by using any of these established approaches
failed to produce infectious virus (data not shown). Results
indicated that capped, in vitro-transcribed MNV RNA is
not translated efficiently when transfected into cells (data
not shown) and that VACV infection can have a
detrimental effect on MNV replication (Fig. 2a). Levels of
the viral RNA-dependent RNA polymerase NS7 and the
minor capsid protein VP2 in cells transfected with VPg-
linked RNA were reduced significantly when cells had
previously been infected with a VACV expressing T7 RNA
polymerase (MVA-T7) (Wyatt et al., 1995; Fig. 2a). This
reduction in NS7 and VP2 resulted in a decrease of
approximately 200-fold in virus yield (Fig. 2a). In contrast,
prior infection of cells with an FWPV recombinant
expressing T7 RNA polymerase (FPV-T7) (Britton et al.,
1996) had no effect on NS7, VP2 or virus titre (Fig. 2a).
A comparative analysis of the ability of T7 polymerase-
expressing poxviruses to drive efficient expression of MNV
proteins from a cDNA expression construct containing the
entire MNV genomic RNA (pT7:MNV-G; Fig. 1b)
revealed that similar levels of NS7 were synthesized in
cells infected with either MVA-T7 or FPV-T7 (Fig. 2b). The
viral capsid proteins VP1 and VP2 were, however,
Norovirus reverse genetics
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encompassing the MNV genomic RNA (data not shown).
FWPV expressing T7 RNA polymerase allows
recovery of MNV
Given our observation that FPV-T7 had no deleterious
effect on MNV replication, yet was able to drive efficient
expression of MNV proteins, the ability of FPV-T7 to allow
the recovery of genetically defined norovirus in tissue
culture was examined (Fig. 3). FPV-T7-infected cells were
transfected with a cDNA construct containing the full-
length MNV genomic cDNA (pT7:MNV-G; Fig. 1b), a
similar construct that contained a frame-shift mutation in
the viral RNA-dependent RNA polymerase NS7
(pT7:MNV-G
FS; Fig. 1b) or a derivative of this construct
in which the frame-shift mutation had subsequently been
repaired (pT7:MNV-G
FS/R). To examine the requirement
for the viral capsid proteins VP1 and VP2, cells were co-
transfected with either empty vector or a cDNA construct
containing the MNV subgenomic RNA (pT7:MNV-SG).
Western blot analysis demonstrated that high levels of NS7
were detected in cells transfected with either VPg-linked
viral RNA or pT7:MNV-G (Fig. 3a). As predicted, a
truncated NS7, referred to as NS79, was detected in cells
transfected with pT7:MNV-G
FS (Fig. 3a), whereas full-
length NS7 was detected in cells that had been transfected
with a construct in which the frame-shift mutation had been
repaired (pT7:MNV-G
FS/R; Fig. 3a). The viral capsid
proteins VP1 and VP2 were only detected in cells transfected
with the subgenomic cDNA expression construct
pT7:MNV-SG [Fig. 3(a) for VP1; data not shown for VP2].
As a first indication of the presence of encapsidated MNV
RNA, the generation of nuclease-resistant MNV RNA was
examined by RT-PCR of lysates from transfected cells that
had been treated extensively with nucleases. Nuclease-
resistant genomes were present in samples from cells
transfected with VPg-linked viral RNA or a combination of
MNV genomic and subgenomic cDNA constructs. To
confirm that the production of encapsidated, nuclease-
resistant viral RNA was the result of authentic virus
replication by the viral RNA-dependent RNA polymerase
NS7, the effect of a frame-shift mutation in NS7 on the
production of nuclease-resistant viral RNA was examined
(Fig. 3b). Nuclease-resistant RNA was not detected in the
lysates from cells transfected with a cDNA construct
containing a frame shift in NS7 (pT7:MNV-G
FS), but was
detected readily when cells were transfected with an
identical construct in which the frame shift had been
repaired (pT7:MNV-G
FS/R; Fig. 3b).
The presence of infectious virus was subsequently con-
firmed by the ability to passage infectivity repeatedly to
RAW 264.7 murine macrophages and confirmed by
Western blot analysis of infected cells (data not shown).
Infectious virus was reproducibly produced only from cells
that had been transfected with purified viral RNA or
transfected with cDNA constructs for both the full-length
Fig. 2. Analysis of the effect of poxvirus infection on MNV
replication. (a) BHK cells were mock-infected (M) or infected with
either VACV (MVA-T7) or FWPV (FPV-T7) expressing T7 RNA
polymerase and subsequently transfected with MNV VPg-linked
RNA. Levels of the viral RNA-dependent RNA polymerase (NS7)
and minor capsid protein (VP2) were analysed by Western blotting
with rabbit polyclonal antisera. In parallel, the virus yield was
determined and expressed as TCID50 per 35 mm dish.
Transfections were carried out in triplicate; error bars represent
SD. (b) BHK cells were either mock-infected (M) or infected with
MVA-T7 or FPV-T7 and subsequently transfected with a cDNA
construct containing the entire MNV genome under the control of a
T7 RNA polymerase promoter (pT7:MNV-G). NS7 expression
levels were subsequently analysed by Western blotting.
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frame-shift mutation in NS7 prevented the recovery of
infectious virus, which was subsequently recovered when
the mutation was repaired (Fig. 3a).
Recovery of genetically tagged MNV
To confirm that the reverse-genetics system allowed the
recovery of genetically defined noroviruses, an additional
BglII restriction site was introduced into the MNV genome
within the region encoding NS7. A single-nucleotide
change (C to A) at position 3959 resulted in the
introduction of a BglII site (Fig. 4a). Recombinant viruses
were recovered from cells co-transfected with a cDNA
expression construct for the viral subgenomic RNA
(pT7:MNV-SG) along with either the wild-type full-length
genomic cDNA construct (pT7:MNV-G) or an identical
construct containing the additional BglII restriction site
(pT7:MNV-G/BglII). The recovered viruses, referred to as
CW1-R and CW1-Bgl, were subsequently amplified in
tissue culture, and RT-PCR analysis of the region encoding
NS7 was performed by using primers 3734F and 4450R.
BglII digestion of the 746 bp amplified products demon-
strated the presence of a single BglII site in the amplicons
from the parental and recombinant MNV, CW1 and CW1-
R (Fig. 4b). However, an additional BglII site was present in
the amplicon generated from the BglII-tagged virus, as
evident by the generation of a 107 bp fragment (CW1-Bgl;
Fig. 4b). Direct sequencing of the amplicons confirmed the
presence of the additional BglII site (Fig. 4c). The entire
sequence of the recovered viruses was determined by RT-
PCR combined with 59 and 39 RACE, and no additional
nucleotide changes were observed in either CW1-R or
CW1-Bgl.
The phenotype of the viruses recovered entirely from
cDNA (CW1-R and CW1-Bgl) was subsequently compared
with that of the parental MNV CW1 by examining both
plaque size and growth characteristics (Fig. 5). The growth
characteristics of CW1-R and CW1-Bgl were identical to
those of the parental virus CW1 (Fig. 5).
The 3§-terminal nucleotide of the MNV genome is
critical for efficient recovery
Our initial results indicated that recovery of MNV from
cDNA required the expression of both the viral genomic
and subgenomic RNAs (Fig. 3). However, during the
course of the study, it became apparent that the 39-terminal
nucleotide immediately upstream of the poly-A tail in the
cDNA expression construct pT7:MNV-G did not match
the MNV 1 consensus sequence derived from the mouse
brain homogenate (GenBank accession no. AY228235).
The terminal nucleotide directly upstream of the poly-A
tail in all MNV strains sequenced to date is thymidine (T);
however, in the cDNA construct pT7:MNV-G, the
terminal nucleotide was cytosine (C) (Fig. 1b). Sequence
analysis of the subgenomic RNA expression construct
indicated that it matched the MNV consensus in that the
terminal nucleotide was a thymidine (Fig. 1b). The
sequence of both CW1-R and CW1-Bgl indicated that, in
each case, the terminal nucleotide matched the MNV
consensus sequence, namely thymidine (data not shown).
To determine whether the apparent requirement for the
subgenomic RNA was due to the 39-terminal mutation in
Fig. 3. Recovery of genetically defined noro-
viruses in tissue culture. (a) Western blot
analysis of BHK cells transfected with either
purified VPg-linked MNV RNA (vRNA) or
plasmids expressing the cDNA encompassing
the MNV subgenomic RNA [pT7:MNV-SG
(SG)], genomic RNA [pT7:MNV-G (G)],
genomic RNA containing a frame-shift muta-
tion in the region coding for NS7 [pT7:MNV-
G
FS (G
FS)] or the repaired derivative
[pT7:MNV-G
FS/R (G
FS/R)]. Samples where
infectious virus was recovered are indicated
by +. (b) RT-PCR analysis demonstrating the
presence of nuclease-resistant MNV RNA in
nuclease-treated supernatants. PCRs were
carried out with and without the prior addition
of reverse transcriptase (RT). Positive and
negative controls for PCR amplification
(PCR” and PCR+) contained nuclease-free
water or a plasmid encoding the MNV genomic
RNA, respectively. Size of molecular mass
markers is indicated.
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generate the construct pT7:MNV-G 39Rp and an addi-
tional construct was generated in which a hepatitis delta
virus ribozyme was inserted after the poly-A tail
(pT7:MNV-G 39Rz; Fig. 1b). Results indicated that high
levels of NS7 were produced from these constructs, but that
the viral capsid proteins VP1 and VP2 were undetectable
by Western blot unless cells were co-transfected with a
subgenomic RNA expression construct (data not shown).
Interestingly, despite the undetectable levels of the capsid
proteins, infectious virus was generated when cells were
transfected with the constructs containing the correct 39-
terminal nucleotide, pT7:MNV-G 39Rp or pT7:MNV-G
39Rz, alone (Table 1). Our studies also indicated that the
inclusion of a hepatitis delta virus ribozyme at the 39 end of
the viral genome increased the efficiency with which virus
was recovered (Table 1). Infectious virus was only detected
72 h post-transfection when cells were co-transfected with
the subgenomic RNA expression construct along with the
construct containing an incorrect terminal nucleotide
(pT7:MNV-G; Table 1). However, infectious virus was
detected 24 h post-transfection if cells were transfected
with constructs containing the correct 39-terminal nucle-
otide, pT7:MNV-G 39Rp or pT7:MNV-G 39Rz (Table 1).
The yield of virus was greater when a hepatitis delta virus
ribozyme was included at the 39 end of the viral genome
(Table 1), suggesting that a free 39 end may be required for
efficient virus recovery.
Fig. 4. Recovery of genetically marked MNV.
(a) Schematic representation of the mutated
region of the MNV genome. The additional
BglII restriction site introduced in the recom-
binant virus CW1-Bgl is indicated by an
asterisk. (b) RT-PCR amplification and sub-
sequent digestion of the amplified region,
indicating the presence of an additional BglII
site in the mutated virus CW1-Bgl that is
absent in the parental recombinant CW1 virus
derived from cDNA (CW1-R) or tissue culture-
adapted MNV (CW1). Size of molecular mass
markers is indicated (in bp). (c) Sequencing
chromatogram of the RT-PCR products
encompassing the mutated region of CW1
and CW1-Bgl. The nucleotide change intro-
duced in CW1-Bgl is underlined; the intro-
duced BglII site is indicated by a black line.
Fig. 5. Growth characteristics of noroviruses recovered from cDNA. Plaque phenotype (a) and one-step growth-curve analysis
(b) of wild-type MNV (CW1, #), MNV recovered entirely from cDNA (CW1-R, h) and the recombinant MNV containing the
additional BglII site (CW1-Bgl, g).
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Our work described above relied exclusively on the use of
the BHK (baby hamster kidney) cell line, due to its high
efficiency of transfection and our observation that
transfection of purified viral RNA resulted in the produc-
tion of .10
6 TCID50 from a 35 mm dish (Fig. 2a). Hence,
this would indicate that all of the necessary intracellular
factors required for MNV replication are present in
hamster cells, despite our observation that they cannot be
infected (data not shown). Several attempts to recover
MNV from cDNA using the RAW 264.7 cell line, which is
permissive to viral infection, failed to lead to the
production of infectious virus. This was probably due to
the low efficiency of transfection (data not shown). To
begin to optimize and increase the efficiency of virus
recovery, the yield of virus from a number of different cell
lines was examined following transfection with the
infectious clone containing a correct 39-terminal nucleo-
tide and a 39 ribozyme (Table 2). The BHK cell line and a
derivative modified to express T7 RNA polymerase (BSR-
T7) were found to produce the highest yields of virus
(Table 2), on average approximately 3.36610
4 TCID50 per
35 mm dish. The BSR-T7 cell line was examined as a
potential method of recovering virus in the absence of
FPV-T7 infections; however, in all cases, infectious virus
was only obtained when cells had previously been infected
with FPV-T7. The Huh 7.5 cell line, previously reported to
be deficient for the antiviral sensor Rig-I (Sumpter et al.,
2005), was also examined and was also found to yield
relatively low levels of virus from cDNA (approx.
2.4610
4 TCID50 per 35 mm dish; Table 2). The typical
yield from 293T cells was approximately 6610
3 TCID50
per 35 mm dish (Table 2). Transfection of the majority of
cells examined with VPg-linked viral RNA resulted in the
production of .10
7 TCID50 per 35 mm dish (Table 2),
indicating that all cells examined were capable of efficient
MNV replication. Vero cells, defective for interferon
production (Emeny & Morgan, 1979), yielded relatively
low levels of virus when transfected with VPg-linked viral
RNA (approx. 1.9610
5 TCID50 per 35 mm dish; Table 2)
and no virus was recovered by using the reverse-genetics
system (Table 2). This may reflect a low transfection
efficiency or the effect of the increased cytopathic effect
that FWPV infection appeared to cause in this cell line
(data not shown).
DISCUSSION
In this report, we describe the generation of the first
norovirus reverse-genetics system, using an FWPV recom-
binant to deliver T7 RNA polymerase. Previously described
reverse-genetics systems for FCV (Sosnovtsev et al., 2002;
Thumfart & Meyers, 2002) have relied on the use of a
VACV recombinant to drive T7 RNA polymerase expres-
sion; however, our studies indicated that VACV infection
had a negative effect on the replication of MNV. The first
T7 RNA polymerase recombinant VACV, vTF7-3 (Fuerst
Table 1. Efficiency of recovery of MNV
All cells were infected with FPV-T7 prior to transfection. See Methods for details of the
constructs used. Virus titre was determined at 24 and 72 h post-transfection and expressed as
TCID50 per 35 mm dish. 2, No detectable virus was generated.
Construct Virus yield at indicated time post-transfection
24 h 72 h
pT7:MNV-G 22
pT7:MNV-G+pT7:MNV-SG 2.00610
2 2.00610
3
pT7:MNV-G 39Rp 2.00610
3 6.32610
3
pT7:MNV-G 39Rp
+pT7:MNV-SG
6.32610
3 3.56610
3
pT7:MNV-G 39Rz 3.56610
4 1.12610
4
pT7:MNV-G 39Rz
+pT7:MNV-SG
1.12610
4 3.56610
3
Table 2. Yield of MNV from various cell lines
All cells were infected with FPV-T7 prior to transfection to control for
any effects of FPV infection on MNV replication. Cells were then
transfected with purified VPg-linked viral RNA (vRNA) or the MNV
infectious clone (pT7:MNV-G 39Rz). Virus yield was determined
24 h post-transfection and expressed as TCID50 per 35 mm dish.
Assays were performed a minimum of three times and representative
data from one experiment are shown. 2, No detectable virus was
generated.
Cell type vRNA pT7:MNV-G 3§Rz
BHK 1.00610
7 3.36610
4
BSR-T7 6.00610
7 3.36610
4
293T 3.36610
7 6.00610
3
Huh 7.5 6.00610
7 2.40610
4
Vero 1.90610
5 2
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replication-competent, i.e. capable of lytic replication in a
range of mammalian and animal cell types. Like the
parental virus, vTF7-3 shuts down most host-gene expres-
sion, but proved extremely useful for high-level expression
of foreign genes. However, presumably because of its
cytopathic nature, it proved inhibitory to the replication of
some viruses and has been less useful for the recovery of
RNA viruses from full-length cDNA clones. T7 RNA
polymerase recombinants of the host range-restricted
VACV MVA were therefore developed (Sutter et al.,
1995; Wyatt et al., 1995). Restricted for productive
replication to avian cells and just a few mammalian cell
lines, these recombinants are less lytic in most cell lines
(although they can still induce cytopathic effects, especially
at high m.o.i.). As a consequence, these recombinants have
been used successfully to recover several RNA viruses from
full-length cDNA clones, including a vaccine strain of
rinderpest virus (Baron & Barrett, 1997), measles virus
(Schneider et al., 1997), Sendai virus (Leyrer et al., 1998),
mumps virus (Clarke et al., 2000), canine distemper virus
(Gassen et al., 2000), bovine respiratory syncytial virus
(Yunus et al., 2001) and FCV (Thumfart & Meyers, 2002).
MVA is, however, highly cytopathic for some cells and cell
lines, including many primary mammalian (but not
primate) cells (Das et al., 2000). Where such cells are
required for propagation of, for instance, field strains of
rinderpest virus, the MVA-induced cytopathic effect
appears to compromise T7 RNA polymerase-mediated
virus recovery (Das et al., 2000). Under such circum-
stances, FPV-T7 has often proved capable of virus rescue
(Boot et al., 1999; Peeters et al., 1999; Das et al., 2000;
Casais et al., 2001). Even in cells in which both MVA and
FWPV can replicate (i.e. avian cells only) or in cells in
which both MVA and FWPV cause cytopathic effects, FPV-
T7 can often still rescue when MVA cannot, probably
because of the slower replication dynamics of FWPV
compared with MVA.
Also worth noting is the fact that the T7 RNA polymerase
in the MVA-T7 used in this study is under the control of a
late (p11) poxvirus promoter (Wyatt et al., 1995), whereas
that in FPV-T7 is under the control of the early/late
poxvirus promoter, p7.5 (Britton et al., 1996). It is
conceivable that the use of an MVA-T7 expressing T7
RNA polymerase from an early/late promoter (Sutter et al.,
1995) might have proved capable of rescuing MNV.
However, the observation that equivalent levels of MNV
proteins were expressed from pT7:MNV-G in cells
infected by either MVA-T7 or FPV-T7 argues somewhat
against this. The inhibitory effect of MVA-induced
cytopathic effect on expression from VPg-linked RNA
might have been countered by the use of cytosine
arabinoside, which blocks MVA genome replication. Such
a strategy was used successfully to rescue measles virus
(Kovacs et al., 2003), but again, it would have required the
use of an MVA with T7 polymerase under the control of an
early or early/late promoter.
Our inability to recover MNV by transfection of in vitro-
transcribed, capped or uncapped RNA is in contrast to
previous reports on FCV (Sosnovtsev & Green, 1995;
Thumfart & Meyers, 2002), PEC (Chang et al., 2005) and
RHDV (Liu et al., 2006). It is probable that this simply
reflects the poor stability of the RNA or the inability of the
host-cell translation machinery to translate capped or
uncapped MNV RNA efficiently. Indeed, our previous
work on calicivirus translation would indicate that VPg is
required for efficient translation of calicivirus RNA
(Goodfellow et al., 2005; Chaudhry et al., 2006). We have
also demonstrated that, despite the ability of MNV VPg to
interact with eIF4E, VPg-linked MNV viral RNA is able to
translate in the absence of eIF4E in vitro (Chaudhry et al.,
2006). This indicates that translation initiation on MNV
RNA requires a subset of initiation factors different from
that required by capped host-cell mRNAs. Our unpub-
lished data would confirm that in vitro translation of
capped or uncapped MNV RNA is inefficient compared
with that of VPg-linked viral RNA (data not shown).
During our study, we also examined the ability of the BSR-
T7 cell line, a BHK cell line derivative that expresses T7
RNA polymerase constitutively, to allow the recovery of
MNV in the absence of FWPV infection (Table 2). This cell
line was chosen due to the reported success in recovery of
respiratory syncytial virus (Buchholz et al., 1999) and
bunyaviruses (Lowen et al., 2004), as well as a potential
method of helper-free virus recovery. However, we failed to
detect MNV protein expression after transfection of the
BSR-T7 cell line with MNV cDNA constructs (data not
shown). Protein expression and infectious virus were only
detected after prior infection with FPV-T7 (data not
shown). This may be due to low levels of RNA synthesis in
these cells in the absence of FPV-T7 infection or, as
described above, to the fact that the uncapped MNV
transcripts produced in this cell line are either unstable or
poorly translated. Although previous reports would suggest
that between 5 and 10% of the transcripts produced by T7
RNA polymerase in VACV-infected cells are capped
(Fuerst & Moss, 1989), similar studies have not been
carried out for FPV-T7. It is likely that some of the
transcripts produced by using the FPV-T7 system are
capped by the fowlpox capping enzymes; however, future
studies would be required to confirm this.
Given the previously reported role of interferon in
controlling calicivirus replication (Karst et al., 2003;
Chang et al., 2004; Wobus et al., 2004), we examined the
recovery of virus by using the reverse-genetics system from
cell lines defective for various aspects of the interferon
response (Vero and Huh 7.5 cells). However, the yield of
virus from these cell lines was no greater than that obtained
from cells in which the interferon system was intact (Table
2). In fact, the Vero cell line, defective for interferon
synthesis (Emeny & Morgan, 1979), failed to recover any
infectious virus and appeared to replicate MNV to only low
levels. Further studies also demonstrated that expressing
the V protein from simian virus 5, which is known to lead
Y. Chaudhry, M. A. Skinner and I. G. Goodfellow
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no stimulatory effect on MNV recovery in 293 cells (data
not shown). Hence, our data would indicate that the
interferon system plays no role in the restriction of virus
recovery using the reverse-genetics system, although
further studies are warranted.
Our results would also suggest that the sequence of the 39-
terminal nucleotide of the MNV genome is critical for
efficient recovery, as constructs containing an incorrect 39-
terminal nucleotide required the co-expression of the
MNV subgenomic RNA for recovery (Fig. 3a; Table 1).
Interestingly, viruses recovered by using the genomic RNA
construct that contained an incorrect 39-terminal nucleo-
tide appeared to correct the 39-terminal nucleotide to
match that present in all previously sequenced MNV
strains (thymidine; data not shown). It is possible that the
repair of the 39-end defect was the result of low-frequency
recombination between the genomic and subgenomic
RNAs; however, further studies would be required to
confirm this. The inclusion of a hepatitis delta ribozyme at
the 39 end of the viral genome was found to increase virus
yield and resulted in maximal virus production 24 h post-
transfection (Table 2), possibly indicating that a free 39 end
is required for efficient virus replication.
Seroprevalence studies have highlighted that, as well as
functioning as a model for the human noroviruses, MNV is
a significant pathogen in its own right, with 22% of mouse
colonies in the USA and Canada found to be seropositive
(Hsu et al., 2005). Recent studies have also highlighted the
fact that numerous strains appear to circulate, which can
differ markedly in their ability to replicate and cause
disease in the host (Hsu et al., 2006; Mumphrey et al.,
2007). As more strains are identified, by combining
sequence data, the mouse model and the reverse-genetics
system described herein, it will now be possible to correlate
sequence variation with differences in norovirus patho-
genicity. Undoubtedly, such studies will facilitate the
identification of viral and host-cell factors required for
norovirus pathogenesis and will aid our ability to control
members of this economically important family of viruses.
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